Do Corporate Alliances Affect Biotechs' Market Performance?
Is there a positive correlation between the number of corporate alliances biotechs have signed and their success at maintaining, or growing, their market valuations since their IPOs? To find out, we took the forty largest biotech IPOs completed in 1996 and 1997 and plotted their recent market valuations and percentage gain or loss over their IPO valuations against the number of significant corporate outlicensings they had signed since IPO.
You may also be interested in...
Pharma is looking to GAVI to oversee a fair distribution and avoid ‘vaccine nationalism’ – but countries can still sign bilateral deals with companies.
The US agency has released a document explaining what COVID-19 testing supplies may be substituted.
Marketing consultant Buzzback surveyed 800 consumers in March, prior to novel coronavirus shutdowns in the two countries, to identify ingredients that offer opportunities for brands in health care, wellness and skin care.